Claritas Rx’s Post

From patient screening through cell product infusion and to LTFU, patient journey has numerous risks that can de rail the clinical progress of the cell therapy program. Learn how to build in the risk mitigation strategies in your clinical program

"I started looking for trials; they often weren’t what I was looking for, I couldn’t tell if they were FDA-authorized, and I later found that a lot of them were not FDA-authorized... I more or less ended up abandoning that idea.” - Jennifer Camel-Toueg, Mother of a teenaged ulcerative colitis patient seeking alternative treatments. Stories like these are what sparked our founder Keith March to develop an online platform to provide patients with an accessible, user-friendly database of FDA-authorized trials in the cell therapy space. Help us make these transformative therapies accessible to everyone. If you're a part of a cell therapy–focused #clinical team, please consider posting your FDA-authorized trials on our website. If you are a #patient, check out our database to find appropriate trials. Learn more at truetrials.org. TrueTrials is officially launching on October 10th. Thanks to #BIO for this great article highlighting our important mission! #celltherapy #patientfocused #clinicalenrollment #ulcerativecolitis #autoimmunedisorders #regenerativemedicine https://lnkd.in/g9ub-W4Z

🌟 Exciting Updates from EMBT 50th Annual Meeting Congress! 🌟 🚀 We had the opportunity to showcase our revolutionary Hub-and-Spoke Model for efficiently delivering cell therapies to patients, led by Jesus Fernandez Sojo. As leaders in cord blood banking, transplantation, and the incorporation of CART technology from the industry, we're proud to highlight some key aspects of our model: 1. Centralization and Coordination: Our Hub-and-Spoke Model allows us to standardize the quality of all our products across Catalonia, ensuring consistency and excellence in patient care. 2. Cutting-Edge Technology: By investing in automation, we maintain a high level of product safety, leveraging the latest advancements to safeguard patient well-being. 3. Expanded Transplant Activity: We're thrilled to report our capacity to support a high volume of transplant activities, extending our services to hospitals beyond Catalonia, even across Spain. 4. Academic Advanced Therapies:From mesenchymal therapies to TILs (Tumor-Infiltrating Lymphocytes) and VSTs (Virus-Specific T Cells), we offer a diverse range of advanced therapies to hospitals in Catalonia, empowering clinicians with innovative treatment options. 5. Concordia Program: Our Hub-and-Spoke Model serves as a benchmark nationwide through the Concordia Program, showcasing our leadership as one of Europe's foremost cord blood banks. 6. Cord Blood Donation 2.0:Introducing our groundbreaking Cord Blood Donation 2.0 program, enabling the provision of novel treatments with cord blood hematopoietic cells, plasma, and platelets. 7. Cellular Therapy Research: We're driving innovation with research initiatives like the development of immunopotent stem cell lines by Belén Alvarez Palomo and the optimization of bioprocesses in cellular therapy by Joaquim Vives, paving the way for groundbreaking treatments. Thanks to: The EBMT Novartis Terumo Blood and Cell Technologies Fact-Netcord, CAT, Jacie. Hospital Universitari Vall d'Hebron Hospital de la Santa Creu i Sant Pau Barcelona Children's Hospital Sant Joan de Déu Hospital Universitari Germans Trias i Pujol Hospital Universitari de Bellvitge Clinica Mutua de Terrassa Hospital Universitari de Girona Dr. Josep Trueta - Atenció Primària ICS Girona Hospital Universitari Joan XXIII Catalan Institute of Oncology

Cell therapy is an innovative approach being explored for the treatment of Parkinson's disease, aiming to replace or regenerate dopamine-producing neurons that are lost in the brains of individuals with the condition. Although it is still an area of active research, and more studies are needed to fully understand its safety, efficacy, and long-term effects; the early results seems to be encouraging! Glad to see some hope in the horizon for treatment of Parkinson's disease 👏 #bayer #pdtreatment

Wow! A new study shows clinical responses to Ide-cel (anti-BCMA CART) are correlated with CD8+ T cell expansion, even though #persistence was not essential for durable remission. This study challenges the current dogma that “persistence is king” and suggests that engineering attempts to increase persistence may not be as pivotal as once thought. This may also have implications for perfecting #allo persistence which has been the major drawback of allo cell therapy naysayers. MAJOR Question: should we be prioritizing more potent, effective CARs that may NOT persist over CARs that persist but are immunosuppressed or exhaust? 🤔 https://lnkd.in/e5TzKYTa #MultipleMyeloma #CART

Must read CAR-T paper. I have been messaging this for a while: You DO NOT need the product to persist for durable remission. CD8+ expansion was correlated to response, not persistence. Should apply to allo as well. See Caribou Biosciences and their PD1 edit (extends time of CAR-T function, not for increased persistence).

Cell therapy is breaking new ground in #cancerresearch! Shouldn't standardization be a topic that we are all considering? Here's an interesting blog that discusses how we can improve our research efforts.

Exploring Autologous Cell Therapy Logistics: Overcome global challenges in site selection, patient recruitment, scheduling precision, and compliance for successful trials. Pave the way for personalized medicine. #CellTherapy #ClinicalTrials #PersonalizedMedicine

🔬💉 Exciting developments in the world of cell therapy! Check out this insightful article highlighting the rise of both autologous and allogeneic approaches as the cell therapy market booms. While autologous therapies lead the charge, offering personalized treatments albeit with higher costs and longer manufacturing times, allogeneic therapies present a promising off-the-shelf alternative, potentially cutting wait times for patients. As advancements continue, both approaches are carving out their niches in the treatment landscape, with big pharma investments pouring in to drive innovation and accessibility. Read the full article to explore the evolving dynamics of the cell therapy market and the bright future ahead #CellTherapy #Innovation #Biotechnology #MedicalResearch #Healthcare #PrecisionMedicine #autologous #allogeneic #landscape #treatment https://lnkd.in/ev6FDnzR

BLOG ALERT: Spotlight on Cell Therapy and the Importance of Sample Prep Standardization - check out our newest addition to our blog!